Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

"Today, Adamas announces FDA approval of an extended release amantadine capsule called GOCOVRI. This drug will provide a practical once a day solution for dyskinesia management and reducing "off" time. Patients who are currently well managed using multiple doses per day of generic amantadine for dyskinesia will not likely derive additional symptomatic benefits from switching to once a day dosing; however, patients experiencing side effects from amantadine may wish to discuss options with their neurologist.

Both GOCOVRI and generic amantadine use is linked to a risk of side effects such as dizziness, hallucinations or blotching on the skin of the legs.  If you are considering starting this medicine or switching to this medicine we recommend consulting with your doctor.

In an independent Parkinson's Foundation study prior to this approval, we found that generic amantadine use improved dyskinesia in patients.  However, amantadine use does have a risk of side effects including insomnia and hallucinations. GOCORVI has been designed to limit the risk of these complications and it will not carry generic amantadine's warning for insomnia."

Call our Helpline, 1-800-4PD-INFO, or visit www.GOCOVRI.com for more information.

About the Parkinson's Foundation

The Parkinson's Foundation is working toward a world without Parkinson's disease. Formed by the merger of National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF), the mission of the Parkinson's Foundation is to invest in promising scientific research that will end Parkinson's disease and improve the lives of people with Parkinson's, and their families, through improved treatments, support and the best care. For more information, visit www.parkinson.org, or call (800) 4PD-INFO (473-4636).

About Parkinson's Disease (PD)

Affecting an estimated one million Americans and 10 million worldwide, PD is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression and anxiety A feeling of nervousness, worried thoughts and physical distress.). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.

# # #

Friday, August 25, 2017
Parkinson’s Foundation Welcomes New Patient Advisors
Wednesday, May 24, 2017

Five New Members Added to Advisory Council to Improve Lives of People Living With Parkinson’s

New York, NY, and Miami, FL — The Parkinson’s Foundation is pleased to welcome five new members to its People with Parkinson’s Advisory Council.  The appointments reflect the foundation’s ongoing commitment to engage with the community in its work to create a world without Parkinson’s disease.

Fifth Annual Celebrate Spring Boston Raises More Than $30,000 for Parkinson’s Foundation
Thursday, May 11, 2017

Boston Area Residents Inspire Fellow Young Professionals to End Parkinson’s

Parkinson’s Foundation Welcomes Paul H. Nathan to Board of Directors
Wednesday, May 3, 2017

New York, NY and Miami, FL — The Parkinson’s Foundation is pleased to announce the election of financial services executive Paul H. Nathan of San Francisco, CA, to its Board of Directors. The appointment was announced following a meeting of the board on April 27.

Parkinson’s Foundation to Host “World Without Parkinson’s” Scientific Symposium on June 1 in NYC
Friday, April 21, 2017

The Parkinson’s Foundation invites health innovators to join World Without Parkinson’s on Thursday, June 1 in New York, NY. The cutting-edge scientific event marks the 200th anniversary of James Parkinson’s, “An Essay on the Shaking Palsy.”

FDA Allows Marketing of a Genetic Test for Medical Conditions Including Parkinson’s
Thursday, April 6, 2017

Earlier today, the US Food and Drug Administration (FDA) announced that it will allow direct marketing to consumers of a genetic test that identifies predispositions for 10 medical conditions, including Parkinson’s. Such tests are referred to as direct-to-consumer or DTC.

Parkinson’s Foundation to Host 60th Anniversary Gala on Wednesday, May 31
Monday, March 20, 2017

The 60th Anniversary Gala to benefit Parkinson’s Foundation will take place Wednesday, May 31, 2017 in the Garden Terrace Room at the New York Botanical Garden in the Bronx, NY.  The Gala marks the 60th Anniversary of both the Parkinson ’s Disease Foundation (PDF) and the National Parkinson Foundation (NPF), the legacy organizations of the Parkinson’s Foundation and recognizes their

Parkinson’s Foundation Mourns the Passing of Lewis P. Rowland, M.D.
Friday, March 17, 2017

The Parkinson’s Foundation mourns the loss of Lewis P. “Bud” Rowland, M.D., Emeritus member of its Board of Directors and longtime champion of its work to end Parkinson’s. Dr. Rowland, who also served as President of the Parkinson’s Disease Foundation (PDF) division of the Parkinson’s Foundation for many years, passed away on March 16.

Local Residents Raise Nearly $40,000 for Parkinson’s Research at Scotch & Sangria Event in Closter, NJ
Thursday, March 9, 2017

Proceeds From Fourth Annual Helping Hours Event Benefit Parkinson’s Foundation

Advocates Guide $16 Million in US Department of Defense Parkinson’s Research Funding for Second Straight Year
Tuesday, March 7, 2017

Recently, four Parkinson’s Foundation Research Advocates helped guide $16 million in government funding for Parkinson’s disease (PD) research. This is the second straight year in which our Research Advocates have served as consumer reviewers for research funded by the US Department of Defense (DoD). The group included:

Parkinson’s Foundation Receives Award to Develop National Recommendations to Improve Care for Women with Parkinson’s
Tuesday, February 28, 2017

NEW YORK CITY & MIAMI — The Parkinson's Foundationhas received a $250,000 award to develop new patient-centered recommendations to improve the health of women living with Parkinson’s disease.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.